Since ABCB1 represents a multidrug resistance factor in several malignancies, including glioma[7], we additionally investigated the influence of ABCB1 promoter methylation on patients’ outcome by using a new established pyrosequencing assay to detect the methylation degree in the ABCB1 promoter. This evidence concerns the gene ABCB1 and glioma.